SEC Form 4 · accession 0001209191-17-061874
Pacira BioSciences, Inc. · PCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kristen Marie Williams
Officer — CAO and General Counsel
Period of report
Nov 16, 2017
Accepted (ET)
Nov 20, 2017 · 6:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001396814
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 16, 2017 | M | 2,143 | $25.37 | A | 23,455 | D | |
| Common Stock | Nov 16, 2017 | S | 2,143 | $40.01 | D | 21,312 | D | |
| Common Stock | Nov 17, 2017 | M | 7,857 | $25.37 | A | 29,169 | D | |
| Common Stock | Nov 17, 2017 | S | 7,857 | $40.00 | D | 21,312 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $25.37 | Nov 16, 2017 | M | 2,143 | D | — | Mar 5, 2023 | Common Stock | 2,143 | 7,857 | D |
| Stock Option (Right to Buy)F2 | $25.37 | Nov 17, 2017 | M | 7,857 | D | — | Mar 5, 2023 | Common Stock | 7,857 | 0 | D |
Explanation of responses
- F1The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- F2The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and as to the remaining option shares in successive equal monthly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.